Myra Vision is developing the Calibreye™ Titratable Glaucoma Therapy™ (TGT) Surgical System, which features adjustable outflow to provide personalized intraocular pressure (IOP) management for patients with moderate to severe glaucoma. This system addresses the limitations of conventional surgical options by minimizing complications while allowing ophthalmologists to tailor treatment as patient needs evolve.
Funding
$25M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
CAFounders
Product
Problem
Conventional glaucoma surgeries like trabeculectomy and tube shunts, while effective in reducing intraocular pressure (IOP), can carry increased risk of complications and may not adapt to the evolving treatment needs of individual glaucoma patients over time. Current surgical options may lack the ability to personalize IOP management, potentially leading to suboptimal outcomes for patients with moderate to severe glaucoma.
Solution
Myra Vision is developing the Calibreye™ Titratable Glaucoma Therapy™ (TGT) Surgical System, designed to provide personalized intraocular pressure (IOP) management for patients with moderate to severe glaucoma. The Calibreye TGT system offers adjustable outflow via four settings, allowing ophthalmologists to titrate treatment according to individual patient needs. Implanted using a well-established ab externo delivery technique, the system aims to minimize complications while providing effective IOP control. The low-profile design and biocompatible materials are intended to optimize aqueous drainage and patient comfort.
Target Audience
The primary target audience includes ophthalmologists who treat glaucoma patients and require surgical options that allow for personalized and adjustable IOP management.
Features
- Adjustable outflow with four settings for personalized IOP management
- Utilizes materials with a history of safe use in ophthalmic applications, including silicone and nitinol
- Low-profile design (0.30 mm thick) intended to maximize patient comfort and minimize erosion risk
- Suture eyelets for secure shunt placement
- Visual indication for confirmation of channel settings
- 10.0 x 1.6–mm overall dimensions intended to provide posterior bleb formation to increase aqueous drainage
- Implanted via well-established ab externo delivery